R Lee Douglas Net Worth

The estimated Net Worth of R Lee Douglas is at least $59.7 ezer dollars as of 12 October 2016. R Douglas owns over 1,219 units of Five Prime Therapeutics Inc stock worth over $59,731 and over the last 11 years R sold FPRX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

R Douglas FPRX stock SEC Form 4 insiders trading

R has made over 1 trades of the Five Prime Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently R exercised 1,219 units of FPRX stock worth $1,499 on 12 October 2016.

The largest trade R's ever made was exercising 1,219 units of Five Prime Therapeutics Inc stock on 12 October 2016 worth over $1,499. On average, R trades about 244 units every 0 days since 2013. As of 12 October 2016 R still owns at least 1,219 units of Five Prime Therapeutics Inc stock.

You can see the complete history of R Douglas stock trades at the bottom of the page.

What's R Douglas's mailing address?

R's mailing address filed with the SEC is 2 Corporate Dr, South San Francisco, CA 94080, USA.

Insiders trading at Five Prime Therapeutics Inc

Over the last 11 years, insiders at Five Prime Therapeutics Inc have traded over $158,392,438 worth of Five Prime Therapeutics Inc stock and bought 4,750,507 units worth $20,970,721 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... és Capital Partners Gp, L.L.C..... On average, Five Prime Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $6,730,346. The most recent stock trade was executed by Francis Willard Sarena on 11 December 2020, trading 22,000 units of FPRX stock currently worth $1,078,000.

What does Five Prime Therapeutics Inc do?

Complete history of R Douglas stock trades at Five Prime Therapeutics Inc

Five Prime Therapeutics Inc executives and stock owners

Five Prime Therapeutics Inc executives and other stock owners filed with the SEC include:

• Peder Jensen,
  Director
• Sheila Gujrathi,
  Director
• Mark Mcdade,
  Director
• Kapil Dhingra,
  Director
• Fred E Cohen,
  Director
• Garry A Nicholson,
  Director
• Franklin M Berger,
  Director
• Robert Steven Sikorski,
  SVP and Chief Medical Officer
• Luis Borges,
  SVP, Research
• Kevin Paul Baker,
  SVP, Development Sciences
• Marc Belsky,
  SVP and CFO
• R Lee Douglas,
  Director
• Francis Willard Sarena,
  Chief Strategy Officer
• Aron Marc Knickerbocker,
  President & CEO
• David V Smith,
  Executive Vice President & CFO
• Lewis T Williams,
  Director
• David White,
  See Remarks
• Carol Schafer,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Bryan Irving,
  EVP, Chief Scientific Officer
• Capital Partners Gp, L.L.C....,
  
• Julie Hambleton,
  SVP & Chief Medical Officer
• William Michael Kavanaugh,
  SVP & Chief Scientific Officer
• Brian G Atwood,
  Director
• Lori Lyons Williams,
  Director
• Helen Louise Collins,
  EVP and Chief Medical Officer
• William R Ringo,
  Director
• Thomas Civik,
  President and CEO
• Partners L P/Ilbiotechnolog...,